- November 22, 2026
- Updated 7:43 am
A Journey of Hope: Eliza O’Neill’s Fight Against Sanfilippo Syndrome
- 47 Views
- admin
- November 1, 2026
- Health Human Interest
In a family photo from 2015, Glenn, Beckham, Cara, and Eliza O’Neill capture a moment together. Eliza, diagnosed with Sanfilippo syndrome, smiles brightly. Sanfilippo syndrome is a rare hereditary condition impacting a child’s ability to break down heparin sulfate, leading to severe developmental issues and a shortened lifespan.
As a young child, Eliza loved wearing accessories, often borrowing her mother Cara’s high heels, much to her parents’ concern. However, when Eliza was three, her parents realized her developmental progress was slower than expected, pointing to a pragmatic speech delay. In 2013, a pediatrician colleague advised testing for metabolic disorders. The results confirmed Sanfilippo syndrome. Cara, a pediatrician herself, recalled learning about this disease and dreaded its implications.
Sanfilippo syndrome results from a defective gene, preventing the breakdown of heparin sulfate. As it accumulates, severe complications develop, causing loss of motor and speech abilities, seizures, and typically leading to a shortened life expectancy.
Eliza’s father, Glenn, took some time to process the diagnosis. Upon understanding how fast the condition could progress, he and Cara devoted themselves to seeking treatment.
Research Efforts for Treatment
Researcher Haiyan Fu at Nationwide Children’s Hospital in Columbus, Ohio, started exploring a gene therapy for Sanfilippo in mice in the late-1990s. The therapy used a modified virus to deliver a healthy gene copy to patients’ cells. Fu recognized its potential if applied early. However, funding was a major hurdle, almost causing her to abandon the project in 2009. Families affected by Sanfilippo, determined to aid her, provided financial support, enabling Fu to proceed to the research’s clinical phase.
Funding and Raising Awareness
Glenn O’Neill sought innovative ways to raise funds for a human clinical trial. Collaborating with filmmaker Benjamin Von Wong, they created a viral video in 2014 called Saving Eliza. The video captured public attention, raising over $1 million through GoFundMe swiftly, eventually reaching $2 million. These funds were critical in initiating the first human trial in May 2016.
Buoyed by promising trial results, the biotech industry, including Ultragenyx, took notice. Ultragenyx secured rights to the gene therapy in 2022, continuing its development, and eventually submitted it for FDA review, resulting in approval in September.
The one-time infusion, named Fayuvi, targets early-stage treatment where results are significantly positive. Ideal for very young children, it aims to halt degeneration before substantial loss occurs. Despite its $4 million price tag, Ultragenyx ensures accessibility for all patients.
Reflections on a Long Journey
Following the FDA’s approval, Fu received a call from Cara O’Neill and messages from families involved in the research. Despite the approval, Fu reflected on the lengthy process, acknowledging those lost before a solution came.
Eliza, now almost 17, was the first to receive the experimental therapy at six years old. Although her speech did not return, she uses picture cards and devices to communicate. Eliza continues attending school and enjoys activities like swimming. Glenn O’Neill expresses immense pride in Eliza, recognizing her journey amidst challenges.